9 nov 2020 anni - The FDA grants an EUA for Eli Lilly’s monoclonal antibody treatment, bamlanivimab. Lilly showed that hospitalizations in COVID-19 patients decreased within 28 days, indicating that it prevents severe forms of the disease when administered quickly.